Compare Amylx Pharmaceuticals Inc (AMLX) vs Upstart Holdings Inc (UPST) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

Upstart Holdings (UPST) trades at $32.74, down 1.47% on the day, with a bullish technical signal and neutral oscillators. The company reported a return to profitability in 2025 with $53.60M net income on $1.02B revenue, though recent quarterly earnings missed expectations. Analyst consensus is mixed with a $42.00 price target, and the stock is positioned between key support at $32 and resistance at $34.

The outlook hinges on execution of AI lending growth and funding stability, with upside potential from product expansion, but risks include margin pressure, debt levels, and macroeconomic sensitivity. The stock offers a speculative growth opportunity amid improving fundamentals but requires careful risk management.